Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reveragen BioPharma, Inc.

http://www.reveragen.com/

Latest From Reveragen BioPharma, Inc.

Santhera's Transformation Should Turn Investors' Heads

The Swiss biotech had a tough time after the failure of idebenone for Duchenne muscular dystrophy, but CEO Dario Eklund tells Scrip that with a new soon-to-be submitted compound, vamorolone, it has an effective and much safer alternative to steroids for the treatment of the progressive muscle degeneration genetic disorder.

Rare Diseases Business Strategies

Santhera Raises CHF45m Ahead Of Duchenne Drug Filing

A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.

Business Strategies Financing

Santhera Eyes US Market Potential After DMD Candidate Tests Positive

Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.

Clinical Trials Rare Diseases

Santhera Restructuring: Discontinues Lead DMD Candidate

Switzerland’s Santhera is to restructure its business and seek extra funding after the failure of Puldysa (idebenone) in a Phase III Duchenne muscular dystrophy study at interim analysis.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register